A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
for Glycogen Storage Disease Type Ia
3 locations incl. Orange
Sponsor: Beam Therapeutics Inc.
Sex: All·Age: 18+
Code: NCT06735755·Phase 1, Phase 2·Recruiting